Clinical Trial Update: A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating dabigatran etexilate as the primary treatment for malignancy-associated venous thromboembolism is underway, with status not specified…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

Sponsor: The University of Hong Kong | Conditions: Venous Thromboembolism, Deep Vein Thrombosis | Phase 3 | Status: UNKNOWN